Seattle Children’s Clinic in the United States has started a new biotech company called BrainChild Bio, with the goal of accelerating the development of CAR T-cell therapeutics for central nervous system malignancies.
CAR T-cell therapy, or chimeric antigen receptor T-cell therapy, is a type of treatment that harnesses the power of the body’s immune system to fight cancer.
Seattle Children’s Hospital provided Brainchild Bio with its first share investment, and it will operate individually.
The CAR T-cell therapy project consists of four studies aimed at assessing the initial effectiveness and risks of the therapy in central nervous system malignancies.
The company has stated that they hope to broaden the therapeutic use of cell therapies to address challenging brain tumors such as glioblastoma and brain metastases in the future.
Dr Michael Jensen, the leading scientific executive of Brainchild Bio, commented, “BrainChild Bio is founded with a mission to bring the best ideas forward to push the bounds of scientific discovery in service of children with cancer.”
Jenson continued by stating, “We are steadfast in our commitment to cracking the code of harnessing CAR T-cell technology in CNS tumours and we are uniquely positioned to do so.”
© Copyright 2010-2021 Zenopa LTD. All Rights Reserved.